attruby news - Search News

FDA, ttr and Attruby

GlobalData on MSN · 1d

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM).

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and hospitalization in ATTR-CM patients.

FDA Approves New Drug for Life-Threatening Heart Condition

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults with transthyretin amyloid cardiomyopathy, or ATTR-CM.

9h

BridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

Newsable Asianet News on MSN1d

BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds

BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results